Published in Nutrition on February 01, 2004
Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology (2011) 1.66
Measures of growth in children at risk for Huntington disease. Neurology (2012) 1.59
Energy deficit in Huntington disease: why it matters. J Clin Invest (2011) 1.51
Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One (2007) 1.49
Cardiac dysfunction in the R6/2 mouse model of Huntington's disease. Neurobiol Dis (2006) 1.31
Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders. Curr Alzheimer Res (2012) 1.19
Adipose tissue dysfunction tracks disease progression in two Huntington's disease mouse models. Hum Mol Genet (2009) 1.09
Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum Mol Genet (2010) 1.06
Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body. Histol Histopathol (2008) 0.99
Dietary intake in adults at risk for Huntington disease: analysis of PHAROS research participants. Neurology (2009) 0.98
Intrajugular vein delivery of AAV9-RNAi prevents neuropathological changes and weight loss in Huntington's disease mice. Mol Ther (2014) 0.92
Euglycemic agent-mediated hypothalamic transcriptomic manipulation in the N171-82Q model of Huntington disease is related to their physiological efficacy. J Biol Chem (2012) 0.91
The role of IκB kinase complex in the neurobiology of Huntington's disease. Neurobiol Dis (2011) 0.87
ATXN2-CAG42 sequesters PABPC1 into insolubility and induces FBXW8 in cerebellum of old ataxic knock-in mice. PLoS Genet (2012) 0.86
Upper gastrointestinal findings in Huntington's disease: patients suffer but do not complain. J Neural Transm (Vienna) (2009) 0.86
Relationship of Mediterranean diet and caloric intake to phenoconversion in Huntington disease. JAMA Neurol (2013) 0.83
Maintenance of basal levels of autophagy in Huntington's disease mouse models displaying metabolic dysfunction. PLoS One (2013) 0.81
Volumetric analysis of the hypothalamus in Huntington Disease using 3T MRI: the IMAGE-HD Study. PLoS One (2015) 0.80
Ataxin-2 regulates RGS8 translation in a new BAC-SCA2 transgenic mouse model. PLoS Genet (2015) 0.80
A 24-Hour Study of the Hypothalamo-Pituitary Axes in Huntington's Disease. PLoS One (2015) 0.79
Altered hypothalamic protein expression in a rat model of Huntington's disease. PLoS One (2012) 0.79
A Metabolic Study of Huntington's Disease. PLoS One (2016) 0.79
Hypocretin-1 (orexin A) levels are normal in Huntington's disease. J Neurol (2006) 0.78
Metabolic disruption identified in the Huntington's disease transgenic sheep model. Sci Rep (2016) 0.77
Body composition in premanifest Huntington's disease reveals lower bone density compared to controls. PLoS Curr (2011) 0.77
High Protein Diet and Huntington's Disease. PLoS One (2015) 0.76
Chromosome substitution strain assessment of a Huntington's disease modifier locus. Mamm Genome (2015) 0.76
Analysis of metabolic effects of menthol on WFS1-deficient mice. Physiol Rep (2016) 0.75
No evidence of impaired gastric emptying in early Huntington's Disease. PLoS Curr (2011) 0.75
Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease. Exp Neurol (2016) 0.75
Altered lipid metabolism in Drosophila model of Huntington's disease. Sci Rep (2016) 0.75
Progressive Impairment of Lactate-based Gluconeogenesis in the Huntington's Disease Mouse Model R6/2. PLoS Curr (2015) 0.75
Mutations in EFHC1 cause juvenile myoclonic epilepsy. Nat Genet (2004) 1.98
Hyperglycosylation and reduced GABA currents of mutated GABRB3 polypeptide in remitting childhood absence epilepsy. Am J Hum Genet (2008) 1.64
Repeat interruptions in spinocerebellar ataxia type 10 expansions are strongly associated with epileptic seizures. Neurogenetics (2013) 1.11
Paradoxical effects of repeat interruptions on spinocerebellar ataxia type 10 expansions and repeat instability. Eur J Hum Genet (2013) 1.10
Genotype-phenotype correlations for EPM2A mutations in Lafora's progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype. Hum Mol Genet (2002) 1.05
Juvenile myoclonic epilepsy: linkage to chromosome 6p12 in Mexico families. Am J Med Genet (2002) 1.02
Absence of Multiple Sclerosis and Demyelinating Diseases among Lacandonians, a Pure Amerindian Ethnic Group in Mexico. Mult Scler Int (2012) 0.99
Low frequency of common LRRK2 mutations in Mexican patients with Parkinson's disease. Neurosci Lett (2010) 0.92
The effect of Parkinson's disease and Huntington's disease on human visuomotor learning. Eur J Neurosci (2013) 0.84
Distinct distribution of autosomal dominant spinocerebellar ataxia in the Mexican population. Mov Disord (2007) 0.84
Olfactory dysfunction in hereditary ataxia and basal ganglia disorders. Neuroreport (2003) 0.84
Plasma ceruloplasmin ferroxidase activity correlates with the nigral sonographic area in Parkinson's disease patients: a pilot study. Neurochem Res (2011) 0.83
Mutation analyses of genes on 6p12-p11 in patients with juvenile myoclonic epilepsy. Neurosci Lett (2006) 0.83
Apolipoprotein E epsilon4 allele is associated with Parkinson disease risk in a Mexican Mestizo population. Mov Disord (2007) 0.82
Identification and mutational analysis of candidate genes for juvenile myoclonic epilepsy on 6p11-p12: LRRC1, GCLC, KIAA0057 and CLIC5. Epilepsy Res (2002) 0.82
Use of oral nutritional supplements in patients with Huntington's disease. Nutrition (2005) 0.82
Low concentration of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients: a pilot study. Schizophr Res (2004) 0.81
DNA variants in coding region of EFHC1: SNPs do not associate with juvenile myoclonic epilepsy. Epilepsia (2009) 0.81
Novel Myoclonin1/EFHC1 mutations in Mexican patients with juvenile myoclonic epilepsy. Seizure (2012) 0.81
Clinical and genetic characteristics of Mexican Huntington's disease patients. Mov Disord (2009) 0.81
Presymptomatic diagnosis in Huntington's disease: the Mexican experience. Genet Test Mol Biomarkers (2009) 0.81
Disruption of visual and motor connectivity in spinocerebellar ataxia type 7. Mov Disord (2013) 0.80
Recent developments in the quest for myoclonic epilepsy genes. Epilepsia (2003) 0.79
Liquid chromatographic-fluorimetric method for the estimation of nitric oxide biosynthesis in the central nervous system. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 0.78
Uptake of genetic testing and long-term tumor surveillance in von Hippel-Lindau disease. BMC Med Genet (2010) 0.78
CYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas. Pharmacogenomics (2014) 0.76
Serum leptin is associated with metabolic syndrome in obese Mexican subjects. J Clin Lab Anal (2014) 0.76
Anticipation and intergenerational repeat instability in spinocerebellar ataxia type 17. Ann Neurol (2007) 0.76
Reply to comment on: "Assessment of nitric oxide biosynthesis and peroxynitrite formation within the central nervous system by measuring L-citrulline in the cerebrospinal fluid?". J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.75
Arginine, citrulline and nitrate concentrations in the cerebrospinal fluid from patients with acute hydrocephalus. J Chromatogr B Analyt Technol Biomed Life Sci (2006) 0.75
Phenylpropanolamine and intracranial hemorrhage risk in a Mexican population. Cerebrovasc Dis (2003) 0.75